Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor ... and immediately raised concerns from analysts and investors worried about direct competition in the ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...

Zepbound's prescription growth has surged ahead of Novo Nordisk's rival GLP-1 weight-loss drug Wegovy in recent months after struggles with supply issues ... said the CVS coverage decision will ...

But employers and unions will ultimately determine how much of those savings on Wegovy get shared with members, CVS said ... the weight loss drug market and concerns that Zepbound's sales ...